PLOIDY AS A PROGNOSTIC FACTOR IN OVARIAN-CANCER
PLOIDY AS A PROGNOSTIC FACTOR IN OVARIAN-CANCER
复制标题
DOI：
10.1097/00004347-198301000-00005
复制
发表时间：
1983-01-01
影响因子：
2.4
通讯作者：
TATTERSALL, MHN
中科院分区：
文献类型：
--
作者：
FRIEDLANDER, ML;TAYLOR, IW;TATTERSALL, MHN
用流式细胞术测定了50例卵巢常见上皮性癌的细胞DNA含量，并将肿瘤分为二倍体和非整倍体。肿瘤分期和倍性之间有显著的相关性，所有的二倍体肿瘤都是早期的（p< 0.001）。40%的早期肿瘤（FIGO I期和II期）和所有晚期肿瘤（FIGO III期和IV期）为非整倍体。相似阶段肿瘤之间DNA含量的这种异质性可能允许鉴定具有不同自然史的肿瘤。通过流式细胞术测定的S期细胞的比例是细胞增殖的量度，并且也可能具有预后意义。二倍体肿瘤的S期中位数为9.8%（2.4-14.1%），而非整倍体肿瘤的S期显著更高，为19.6%（7-24.7%; p< 0.05）。在这项研究中，浸润性癌的组织学分级和倍性之间没有关系，但鉴于相对较少的数量和有限的随访，不可能对卵巢癌的所有已知预后因素进行多变量分析。我们的研究结果表明，倍性反映了肿瘤的行为，但长期随访和增加患者的累积是必要的，以评估是否流式细胞术分析的DNA含量将提供临床上重要的信息，卵巢癌。
The cellular DNA content of 50 ovarian common epithelial carcinomas was determined by flow cytometry, and tumours were classified as being either diploid or aneuploid. A significant association between tumour stage and ploidy was demonstrated, with all diploid tumours being of an early stage (p< 0.001). Forty percent of early-stage tumours (FIGO stages I and II) and all late-stage tumours (FIGO stages III and IV) were aneuploid. This heterogeneity with respect to DNA content among tumours of a similar stage may allow the identification of neoplasms with a different natural history. The proportion of S-phase cells determined by flow cytometry is a measure of cellular proliferation and may also be of prognostic significance. Diploid tumours had a median S phase of 9.8%(2.4–14.1%), while aneuploid tumours had a significantly higher S phase of 19.6%(7–24.7%; p< 0.05). In this study there was no relationship between histological grading of invasive carcinomas and ploidy, but in view of the relatively small numbers and limited follow-up, it was_not possible to perform a multivariate analysis of all known prognostic factors in ovarian cancer. Our results suggest that ploidy reflects tumour behaviour, but prolonged follow-up and increased patient accrual is necessary to assess whether the flow cytometric analysis of DNA content will provide clinically important information in ovarian cancer.